CIENCIASMEDICASNEWS: A Complete Toolkit for SARS-CoV-2 Antigen Tests

viernes, 7 de agosto de 2020

A Complete Toolkit for SARS-CoV-2 Antigen Tests

	Antibodies
	The latest antibodies news from News Medical

VHH Antibodies (Nanobodies) Advantages and Limitations

A Complete Toolkit for SARS-CoV-2 Antigen Tests

SARS-CoV-2 antigen test relies on the immunodetection of the viral antigens in biological samples. Sino Biological has developed a panel of antibodies specific to SARS-CoV-2 S&N proteins and antibody pairs that can be used to assemble detection assays for the corresponding antigen.

Find Out More

Antibody Discovery: Should You Switch to Picodroplet Technology?

Leveraging picodroplet-based technology offers a robust, high throughput platform for screening and isolating rare antigen-specific B cells directly from large heterogeneous populations in just two days. By using Cyto-Mine®, researchers can overcome challenges in the antibody discovery process and significantly shorten the antibody discovery workflow.

Implementing liquid handling automation for developing new Antibody-based assays

Over the years Cisbio has developed hundreds of assays. In this application note we report how the MANTIS® liquid handler improve the process on all of the following key points: reproducibility, time, and cost. This work focuses on two types of Homogeneous Time Resolved Fluorescence (HTRF)® detection assays.

Learn More

	What are Neutralizing Antibodies? A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are organisms that cause disease.

	Researchers develop CAR-T cell therapy based on TCR signal transduction The T cell receptor (TCR) is a key receptor that is responsible for detecting tumor antigens in T cells.

	Study shows neo-self antibody as major cause of recurrent pregnancy loss A research group have revealed for the first time in the world the high frequency of a novel autoantibody in women suffering from recurrent pregnancy loss.

	Potential antibody treatment for yellow fever developed in 7 months using Rapid Response Strategy Yellow fever, an acute viral hemorrhagic disease transmitted by infected mosquitoes, infects about 200,000 people and causes an estimated 30,000 deaths each year.